Hamadan University of Medical Science Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT03063879
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Hamadan University of Medical Science

Active Ingredients

Drugs in Phase 4 Trials (2)

daclatasvir (daklinza) (1 trial)

sofosbuvir (sovaldi) (1 trial)

Drugs in Phase 3 Trials (1)

sodium succinate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Kidney Failure, Chronic (Phase 4)

Renal Insufficiency (Phase 4)

Shock (Phase 3)

Shock, Septic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3